MX2022007546A - Interferon-alfa-2 modificado que tiene inmunogenicidad reducida. - Google Patents
Interferon-alfa-2 modificado que tiene inmunogenicidad reducida.Info
- Publication number
- MX2022007546A MX2022007546A MX2022007546A MX2022007546A MX2022007546A MX 2022007546 A MX2022007546 A MX 2022007546A MX 2022007546 A MX2022007546 A MX 2022007546A MX 2022007546 A MX2022007546 A MX 2022007546A MX 2022007546 A MX2022007546 A MX 2022007546A
- Authority
- MX
- Mexico
- Prior art keywords
- interferon
- modified interferon
- reduced immunogenicity
- nucleic acid
- present disclosure
- Prior art date
Links
- 230000005847 immunogenicity Effects 0.000 title abstract 3
- 108010078049 Interferon alpha-2 Proteins 0.000 title 1
- 102100039350 Interferon alpha-7 Human genes 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 abstract 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 abstract 1
- 230000004989 O-glycosylation Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente divulgación se dirige a composiciones que comprenden polipéptidos de interferón-a2 modificado que tienen actividad de interferón-a2 e inmunogenicidad reducida. En algunos aspectos, dichos polipéptidos de interferón-a2 modificado están hiperglicosilados, como por ejemplo mediante la adición de una secuencia peptídica derivada de GM-CSF con múltiples sitios de O-glicosilación. Además, la presente divulgación proporciona composiciones que comprenden una molécula de ácido nucleico que codifica dicho interferón-a2 modificado. La presente divulgación también proporciona composiciones que comprenden una línea celular de expresión de proteínas recombinantes que comprende dicha molécula de ácido nucleico que codifica dicho interferón-a2 modificado; en donde dicha célula de expresión de proteínas recombinantes comprende un plásmido o vector que contiene dicha molécula de ácido nucleico. Asimismo se divulgan composiciones farmacéuticas que comprenden un interferón-a2 modificado que tiene actividad de interferón-a2 con inmunogenicidad reducida, así como métodos de uso de dichas formulaciones farmacéuticas para el tratamiento de afecciones médicas en un sujeto.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ARP190103715A AR117715A1 (es) | 2019-12-17 | 2019-12-17 | Interferón hiperglicosilado con inmunogenicidad reducida |
| PCT/US2020/065246 WO2021126929A1 (en) | 2019-12-17 | 2020-12-16 | Modified interferon-alpha-2 having reduced immunogenicity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022007546A true MX2022007546A (es) | 2022-11-30 |
Family
ID=76478524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022007546A MX2022007546A (es) | 2019-12-17 | 2020-12-16 | Interferon-alfa-2 modificado que tiene inmunogenicidad reducida. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230127506A1 (es) |
| EP (1) | EP4076504A4 (es) |
| JP (1) | JP2023514659A (es) |
| AR (1) | AR117715A1 (es) |
| BR (1) | BR112022011975A2 (es) |
| MX (1) | MX2022007546A (es) |
| WO (1) | WO2021126929A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2023325400A1 (en) | 2022-08-18 | 2025-02-27 | Regeneron Pharmaceuticals, Inc. | Interferon proproteins and uses thereof |
| US20240067691A1 (en) | 2022-08-18 | 2024-02-29 | Regeneron Pharmaceuticals, Inc. | Interferon receptor agonists and uses thereof |
| WO2024238415A1 (en) | 2023-05-12 | 2024-11-21 | Regeneron Pharmaceuticals, Inc. | Interferon receptor antagonists and uses thereof |
| CN116814595B (zh) * | 2023-08-30 | 2023-11-28 | 江苏申基生物科技有限公司 | 一种腺苷脱氨酶突变体及其固定化 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1379555A2 (en) * | 2001-03-02 | 2004-01-14 | MERCK PATENT GmbH | Modified interferon alpha with reduced immunogenicity |
| WO2006020580A2 (en) * | 2004-08-09 | 2006-02-23 | Alios Biopharma Inc. | Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same |
| ATE529442T1 (de) * | 2005-06-03 | 2011-11-15 | Ambrx Inc | Verbesserte humane interferon-moleküle und ihre verwendungen |
| EA014157B1 (ru) * | 2005-06-29 | 2010-10-29 | Йеда Рисерч Энд Дивелопмент Ко. Лтд. | РЕКОМБИНАНТНЫЕ МУТАНТЫ ИНТЕРФЕРОНА α2 (IFNα2) |
| US20080260820A1 (en) * | 2007-04-19 | 2008-10-23 | Gilles Borrelly | Oral dosage formulations of protease-resistant polypeptides |
| UA125637C2 (uk) * | 2014-10-29 | 2022-05-11 | Тева Фармасьютікалз Острейліа Пті Лтд | ЗЛИТИЙ ПОЛІПЕПТИД ІНТЕРФЕРОНУ <font face="Symbol">a2</font>b |
| AR102120A1 (es) * | 2015-09-29 | 2017-02-08 | Univ Nac Del Litoral | Interferón modificado con inmunogenicidad reducida |
| CN112105632A (zh) * | 2018-01-24 | 2020-12-18 | 北京智康博药肿瘤医学研究有限公司 | 细胞因子融合蛋白 |
-
2019
- 2019-12-17 AR ARP190103715A patent/AR117715A1/es unknown
-
2020
- 2020-12-16 WO PCT/US2020/065246 patent/WO2021126929A1/en unknown
- 2020-12-16 MX MX2022007546A patent/MX2022007546A/es unknown
- 2020-12-16 US US17/783,948 patent/US20230127506A1/en active Pending
- 2020-12-16 JP JP2022537837A patent/JP2023514659A/ja active Pending
- 2020-12-16 EP EP20901063.6A patent/EP4076504A4/en active Pending
- 2020-12-16 BR BR112022011975A patent/BR112022011975A2/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022011975A2 (pt) | 2022-08-30 |
| EP4076504A1 (en) | 2022-10-26 |
| EP4076504A4 (en) | 2024-04-10 |
| WO2021126929A1 (en) | 2021-06-24 |
| US20230127506A1 (en) | 2023-04-27 |
| AR117715A1 (es) | 2021-08-25 |
| JP2023514659A (ja) | 2023-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022007546A (es) | Interferon-alfa-2 modificado que tiene inmunogenicidad reducida. | |
| JP2023011697A (ja) | 核酸産物およびその投与方法 | |
| SA521430398B1 (ar) | Ph20 تركيبة صيدلانية، تشمل متغير ودواء هيالورونيداز البشرى، للحقن تحت الجلد | |
| ES2544573T3 (es) | Inhibidores diméricos de afinidad elevada de PSD-95 y su uso para el tratamiento del daño cerebral isquémico y del dolor | |
| CN107075574A (zh) | 铁调素和微型铁调素类似物及其用途 | |
| CN109641034A (zh) | 聚乙二醇化的猪干扰素及其使用方法 | |
| US11141463B2 (en) | Fusion proteins with extended serum half life | |
| AU2005283025A1 (en) | Muteins of fibroblast growth factor 21 | |
| MX2011008094A (es) | Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos. | |
| WO2021146436A3 (en) | Biased il2 muteins methods and compositions | |
| MX2022010175A (es) | Proteinas de union a flt3 y metodos de uso. | |
| NZ708990A (en) | Method for activating helper t cell | |
| WO2022256500A3 (en) | Dll3 targeting trispecific proteins and methods of use | |
| CN110256575A (zh) | 一种长效重组人生长激素融合蛋白及其工程细胞 | |
| WO2022256498A9 (en) | Msln targeting trispecific proteins and methods of use | |
| CA2692358A1 (en) | Recombinant human interferon-like proteins | |
| MX2021011039A (es) | Vectores de adn no virales y usos de estos para expresar agentes terapéuticos con fviii. | |
| WO2022256499A3 (en) | Bcma targeting trispecific proteins and methods of use | |
| PH12022553408A1 (en) | Cytokine conjugates | |
| EP0596969A1 (en) | Igf-ii analogues | |
| PH12021553235A1 (en) | Drug product for enzyme therapy for treatment of homocystinuria | |
| MX2022008748A (es) | Administración oral de péptidos. | |
| KR20170024469A (ko) | 상피세포 성장인자의 활성을 가지는 펩타이드 및 그의 용도 | |
| EP3049433B1 (en) | Fused proteins of granulocyte colony-stimulating factor with other partners of growth factor, preferably with stem cell factor, and method of preparation thereof | |
| US20080200378A1 (en) | KGF polypeptide compositions |